Daily cannabis users with sickle cell disease had fewer hospital admissions despite reporting worse pain | Research

The takeaway

Adults with sickle cell disease who used cannabis daily reported more severe pain episodes but had 1.8 fewer annual hospital admissions and 1.2 fewer ER visits than matched non-users.

Hematologists, sickle cell disease patients, pain medicine clinicians

1.8 fewer annual admissions and 1.2 fewer ER visits among daily cannabis users

What the researchers found

Daily cannabis users with SCD had worse pain episode severity scores than others (56.7 vs. 48.8, p = 0.02) yet had 1.8 fewer annual admissions (p = 0.01) and 1.2 fewer annual ER visits (p = 0.01). Opioid dispensing was similar between groups after matching for age, gender, genotype, hydroxyurea use, and pain impact scores.

Why it matters

Sickle cell disease causes severe pain crises that drive frequent hospitalization. If cannabis use genuinely reduces healthcare utilization without increasing opioid needs, it could have significant clinical implications.

The numbers in context

Daily users: pain severity 56.7 vs. 48.8 (p = 0.02). 1.8 fewer annual admissions (p = 0.01). 1.2 fewer annual ER visits (p = 0.01). Similar opioid amounts dispensed after matching.

How the study worked

Cross-sectional study of adults with sickle cell disease comparing daily cannabis users with non-daily users. Validated patient-reported measures of pain and quality of life. Matched for age, gender, SCD genotype, hydroxyurea use, and pain impact scores.

What this study cannot tell us

Cross-sectional design; cannot determine if cannabis caused the reduction in admissions; self-selection bias (patients who manage well at home may be more likely to choose cannabis); small sample implied by single-center design.

How to read the evidence

Cross-sectional with matching, but cannot determine causation; self-selection bias possible.

When this study was published

Published in 2020.

The bigger picture

The paradox of worse reported pain but fewer hospitalizations in cannabis users suggests cannabis may help manage pain at home rather than eliminating it, reducing the need for acute care.

Questions still open

Does cannabis allow SCD patients to manage pain crises at home that would otherwise require hospitalization? Would an RCT confirm these findings?

Common questions

Why did cannabis users report worse pain but go to the hospital less?

One interpretation is that daily cannabis users may have more severe disease (hence worse pain scores) but cannabis helps them manage crises at home rather than seeking emergency care. Alternatively, personality or coping style differences could contribute to both cannabis use and home management preferences.

Should people with sickle cell disease use cannabis for pain?

This cross-sectional study suggests a promising association, and the authors call for randomized controlled trials. The finding that opioid use was similar between groups (not reduced) suggests cannabis may complement rather than replace conventional pain management.

Read the original research

Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints.

Cannabis and cannabinoid research, 5(3), 255-262

View on PubMed ↗Publisher’s paper ↗

Citation

Curtis, Susanna A; Brandow, Amanda M; DeVeaux, Michelle; Zeltermam, Daniel; Devine, Lesley; Roberts, John D. (2020). Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints.. Cannabis and cannabinoid research, 5(3), 255-262. https://doi.org/10.1089/can.2019.0036